Last $44.12 USD
Change Today -0.91 / -2.02%
Volume 1.1M
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 8000

Fax:

Alkermes Public Limited Company operates as an integrated biopharmaceutical company worldwide. The company has a portfolio of approximately 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders, such as addiction, schizophrenia, and depression. Products and Development Programs Commercial Products RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate the company’s proprietary technologies. They are products of Janssen Pharmaceutica International Inc. (Janssen). RISPERDAL CONSTA uses the company’s polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the company and is marketed and sold by Janssen worldwide. It is approved for the treatment of schizophrenia in the U.S. and in countries in Europe. The U.S. Food and Drug Administration (FDA) approved RISPERDAL CONSTA as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. RISPERDAL CONSTA is also approved for the maintenance treatment of bipolar I disorder in Canada, Australia, and Saudi Arabia. INVEGA SUSTENNA uses the company’s nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA SUSTENNA is approved for the acute and maintenance treatment of schizophrenia in adults in the U.S. Paliperidone palmitate extended-release for injectable suspension is also approved in the European Union (EU) and other countries worldwide, and is marketed and sold in the EU under the trade name, XEPLION. INVEGA SUSTENNA/XEPLION is manufactured and commercialized worldwide by Janssen. AMPYRA/FAMPYRA Dalfampridine extended-release tablets are marketed and sold in the U.S. under the trade name AMPYRA by Acorda Therapeutics, Inc. (Acorda). Prolonged-release fampridine tablets received conditional approval in the EU and are marketed and sold outside the U.S. under the trade name, FAMPYRA by Biogen Idec. The FDA approved AMPYRA as a treatment to improve walking in patients with multiple sclerosis as demonstrated by an increase in walking speed. The product incorporates the company’s technology. AMPYRA and FAMPYRA are manufactured by the company. BYDUREON The company collaborated with Amylin Pharmaceuticals, Inc. (Amylin), a wholly-owned subsidiary of Bristol-Myers Squibb Company (Bristol-Myers), on the development of a once-weekly formulation of exenatide, BYDUREON, which was approved by the FDA in 2012 and received marketing authorization in the EU for the treatment of type 2 diabetes. BYDUREON, a once-weekly formulation of exenatide, the active ingredient in BYETTA (exenatide), uses the company’s polymer-based microsphere injectable extended-release technology. Through their diabetes collaboration, Bristol-Myers and AstraZeneca PLC co-develop and market Amylin's portfolio of products, including BYDUREON. VIVITROL VIVITROL is the once-monthly injectable medication approved by the FDA for the treatment of alcohol dependence and the prevention of relapse to opioid dependence, following opioid detoxification. The medication uses the company’s polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every four weeks. The company developed, and markets and sells, VIVITROL in the U.S., and Cilag sells VIVITROL in Russia and the Commonwealth of Independent States where it is approved for the treatment of alcohol dependence and for opioid dependence. Development Programs Aripiprazole Lauroxil: The company is studying aripiprazole lauroxil for the treatment of schizophrenia. Aripiprazole lauroxil is designed to provide once-monthly dosing of a medication that co

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $44.12 USD -0.91

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $60.89 USD -0.48
Jazz Pharmaceuticals Plc $136.16 USD +0.055
Lupin Ltd 955.65 INR +2.95
Nektar Therapeutics $10.97 USD -0.075
Pacira Pharmaceuticals Inc/DE $66.05 USD -1.67
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings 100.0x
Price/Sales 10.7x
Price/Book 5.8x
Price/Cash Flow 86.8x
TEV/Sales 9.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.